MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT - News) announced today the initiation of the InSiteTM Trial, a post-market study of its commercially available InterStim® Therapy for Urinary Control, a treatment for overactive bladder and urinary retention. The U.S. Food and Drug Administration (FDA) has approved this study, which will aim to enroll more than 450 patients; those who qualify will be randomized to receive either InterStim Therapy or standard medical treatment, including oral medications as determined by their physician. Patients implanted with InterStim Therapy will be followed out to five years. The results of this trial are expected to provide further clinical evidence of InterStim Therapy’s efficacy in treating patients suffering from overactive bladder versus standard medical therapy.
